Parkinson's drug shows promise for eye disease in extension trial
NCT ID NCT03197493
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 29 times
Summary
This study tested a drug called carbidopa-levodopa, normally used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It was a 9-month extension for 35 participants who had already completed an earlier study. The goal was to see if the drug could improve vision and was safe to take long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULA; DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Robert W Snyder, MD, PhD, PC
Tucson, Arizona, 85712, United States
Conditions
Explore the condition pages connected to this study.